| gap-debate-20260410- | Do TREM2 and microglial pruning pathways require population-specific modulation | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Are complement cascade activation thresholds genetically calibrated differently | open | 0.70 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-debate-20260410- | How do mitochondrial haplogroups prevalent in SEA populations affect oxidative s | open | 0.80 | 0.00 | 2026-04-10 | 0 | | mitochondrial-biology |
| gap-debate-20260410- | Do SEA populations exhibit distinct estrogen receptor expression patterns in neu | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Which metabolic pathways are modulated by current AD therapeutics to enable biom | open | 0.71 | 0.00 | 2026-04-10 | 0 | | pharmacology |
| gap-debate-20260410- | Can mitochondrial DNA copy number in CSF extracellular vesicles reliably reflect | open | 0.75 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What is the optimal sampling frequency for CSF lactate/pyruvate ratios to detect | open | 0.78 | 0.00 | 2026-04-10 | 0 | | biomarker-development |
| gap-debate-20260410- | Do sex differences in neurodegeneration reflect therapeutic metabolism or sympto | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Which specific molecular targets downstream of transcription factors like SREBP2 | open | 0.75 | 0.00 | 2026-04-10 | 0 | | drug-development |
| gap-debate-20260410- | Does IL-10 receptor activation in microglia impair amyloid clearance capacity wh | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-debate-20260410- | What are the mechanistic pathways linking astrocyte xCT upregulation to GLT1 glu | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurobiology |
| gap-debate-20260410- | Do PINK1/PARKIN pathway enhancements rescue excitatory neuron vulnerability or c | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Which cell-type vulnerability signatures from SEA-AD single-cell data represent | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | systems-biology |
| gap-debate-20260410- | Does IL-10 receptor activation in microglia impair amyloid clearance capacity wh | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-debate-20260410- | What is the mechanistic coupling between astrocyte xCT cystine transport and GLT | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurobiology |
| gap-debate-20260410- | Do PINK1/PARKIN pathway enhancements rescue excitatory neuron vulnerability or e | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do tissue-specific immune environments affect TREM2 therapeutic strategies a | open | 0.70 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | Do TREM2-mediated Aβ clearance mechanisms translate to meaningful clinical outco | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What are the optimal biomarkers and thresholds for determining neurodegeneration | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can TREM2 receptor switching from agonism to antagonism be achieved safely witho | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What developmental mechanisms control the age-dependent divergence between micro | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How reliable are current microglia-specific markers for distinguishing cell popu | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What CNS niche-specific mechanisms instruct peripheral macrophages to acquire mi | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does oleuropein's direct activation of mitochondrial calcium uptake translat | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms cause mitochondrial calcium uptake to decline specific | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Which microbiome-derived metabolites directly modulate NLRP3 inflammasome activa | open | 0.75 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | How does increased Akkermansia abundance specifically compromise intestinal barr | open | 0.80 | 0.00 | 2026-04-10 | 0 | | gastroenterology |
| gap-debate-20260410- | Can exogenous butyrate supplementation achieve therapeutic concentrations in the | open | 0.85 | 0.00 | 2026-04-10 | 0 | | pharmacology |
| gap-debate-20260410- | Does reduced Prevotellaceae abundance cause PD pathology or result from it? | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Do perivascular inflammation and amyloid clearance failure create self-reinforci | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-debate-20260410- | What is the causal relationship between sleep architecture changes and glymphati | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | sleep-neuroscience |
| gap-debate-20260410- | Can arteriolosclerosis-induced perivascular space compression be mechanically re | open | 0.78 | 0.00 | 2026-04-10 | 0 | | vascular-neurology |
| gap-debate-20260410- | Does chronic melatonin supplementation cause receptor desensitization that negat | partially_addressed | 0.82 | 0.00 | 2026-04-10 | 0 | | neuropharmacology |
| gap-debate-20260410- | Do restored epigenetic biomarkers translate to functional neuronal improvement o | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What is the mechanistic coupling between autophagy flux and chromatin remodeling | open | 0.75 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-debate-20260410- | How can DNMT inhibitors achieve brain-region specificity without systemic genomi | open | 0.80 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Are DNA methylation changes in neurodegeneration causal drivers or protective co | investigating | 0.90 | 0.00 | 2026-04-10 | 1 | 2026-04-26 | neurodegeneration |
| gap-debate-20260410- | Can systemic CD38 activation be achieved without triggering pro-inflammatory res | open | 0.70 | 0.00 | 2026-04-10 | 0 | | neuropharmacology |
| gap-debate-20260410- | How does lactylation of ARF1 mechanistically regulate LRP1-mediated mitochondria | open | 0.75 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What is the optimal temporal window for mitochondrial transfer enhancement in ch | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Do transferred mitochondria from diseased astrocytes carry pathological damage t | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Does early AD represent accelerated aging-related pruning or a distinct patholog | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What are the downstream molecular pathways disrupted by TREM2 loss-of-function v | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Do microglia metabolic states directly control synaptic engulfment capacity inde | open | 0.80 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | Can pathological vs physiological C1q tagging be distinguished at the molecular | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do disruptions in PI3K/AKT and MAPK downstream pathways collectively increas | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the safety and efficacy profiles of IGF-based treatments for Alzheimer' | resolved | 0.86 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does aberrant IGF signaling mechanistically contribute to AD development and | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do reduced oxidative stress and enhanced autophagy mechanistically prevent n | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does CR's metabolic rate effect contradict or support its longevity benefits at | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |